PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2016.31.3.4392016313439Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes MellitusSang Ah Lee, Gwanpyo Koh, Suk Ju Cho, So-Yeon Yoo, Sang Ouk Chinhttp://synapse.koreamed.org/pdf/10.3803/EnM.2016.31.3.439, http://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2016.31.3.439, http://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2016.31.3.439
Diabetes mellitus10.14341/2072-0351-54972010133106-109The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitusMarina Vladimirovna Shestakovahttps://dia-endojournals.ru/dia/article/viewFile/5497/3295, https://dia-endojournals.ru/dia/article/viewFile/5497/3295
Diabetes Research and Clinical Practice10.1016/s0168-8227(97)00069-71997373165-171Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitusSung-Woo Park, Sung-Hee Ihm, Hyung J Yoo, Joong Y Park, Ki-Up Leehttps://api.elsevier.com/content/article/PII:S0168822797000697?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168822797000697?httpAccept=text/plain
Diabetes mellitus10.14341/dm96232018214293-300Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetesNina A. Petunina, Milena Е. Telnovahttps://dia-endojournals.ru/dia/article/viewFile/9623/7382, https://dia-endojournals.ru/dia/article/viewFile/9623/7382
Diabetes mellitus10.14341/dm88042017204286-298Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetesGagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovichhttps://dia-endojournals.ru/dia/article/viewFile/8804/6915, https://dia-endojournals.ru/dia/article/viewFile/8804/6915
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy10.2147/dmso.s275282012165Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic reviewNicole Pinelli, Berlie, Hurrenhttps://www.dovepress.com/getfile.php?fileID=13153
Diabetes10.2337/db18-2231-pub201867Supplement 12231-PUBCombination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) PatientsSASAN FAZELI, NICOLE EHRHARDThttps://syndication.highwire.org/content/doi/10.2337/db18-2231-PUB
Journal of Diabetes and its Complications10.1016/j.jdiacomp.2017.05.01020173181283-1285Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeksLawrence A. Leiter, Jorge Luiz Gross, Francis Chow, Diane Miller, Susan Johnson, Bo Ahrénhttps://api.elsevier.com/content/article/PII:S1056872717301502?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1056872717301502?httpAccept=text/plain
10.21203/rs.2.16671/v32020Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v3, https://www.researchsquare.com/article/rs-7309/v3.html
10.21203/rs.2.16671/v12019Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v1, https://www.researchsquare.com/article/rs-7309/v1.html